Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine

Chaitanya Kurhade, Jing Zou, Hongjie Xia, Hui Cai, Qi Yang, Mark Cutler, David Cooper, Alexander Muik, Kathrin U Jansen, Xuping Xie, Kena A Swanson, Pei-Yong Shi, Chaitanya Kurhade, Jing Zou, Hongjie Xia, Hui Cai, Qi Yang, Mark Cutler, David Cooper, Alexander Muik, Kathrin U Jansen, Xuping Xie, Kena A Swanson, Pei-Yong Shi

Abstract

The newly emerged Omicron SARS-CoV-2 has several distinct sublineages including BA.1, BA.2, and BA.3. BA.1 accounts for the initial surge and is being replaced by BA.2, whereas BA.3 is at a low prevalence at this time. Here we report the neutralization of BNT162b2-vaccinated sera (collected 1 month after dose 3) against the three Omicron sublineages. To facilitate the neutralization testing, we have engineered the complete BA.1, BA.2, or BA.3 spike into an mNeonGreen USA-WA1/2020 SRAS-CoV-2. All BNT162b2-vaccinated sera neutralize USA-WA1/2020, BA.1-, BA.2-, and BA.3-spike SARS-CoV-2s with titers of >20; the neutralization geometric mean titers (GMTs) against the four viruses are 1211, 336, 300, and 190, respectively. Thus, the BA.1-, BA.2-, and BA.3-spike SARS-CoV-2s are 3.6-, 4.0-, and 6.4-fold less efficiently neutralized than the USA-WA1/2020, respectively. Our data have implications in vaccine strategy and understanding the biology of Omicron sublineages.

Trial registration: ClinicalTrials.gov NCT04368728.

© 2022. The Author(s).

References

    1. N Engl J Med. 2021 Oct 21;385(17):1627-1629
    1. Nature. 2021 Apr;592(7852):116-121
    1. Nat Protoc. 2021 Mar;16(3):1761-1784
    1. MMWR Morb Mortal Wkly Rep. 2022 Feb 18;71(7):255-263
    1. N Engl J Med. 2022 Apr 21;386(16):1532-1546
    1. Nature. 2022 Apr;604(7906):553-556
    1. Nat Med. 2021 Apr;27(4):620-621
    1. Lancet. 2022 Feb 26;399(10327):771-773
    1. N Engl J Med. 2022 Apr 21;386(16):1579-1580
    1. mBio. 2022 Apr 26;13(2):e0361721
    1. N Engl J Med. 2021 Mar 8;384(15):1466-1468
    1. Nature. 2020 Oct;586(7830):589-593
    1. Nat Commun. 2022 Feb 9;13(1):852
    1. Cell Host Microbe. 2020 May 13;27(5):841-848.e3
    1. Cell Host Microbe. 2022 Apr 13;30(4):485-488.e3
    1. Euro Surveill. 2022 Feb;27(6):
    1. N Engl J Med. 2020 Dec 17;383(25):2439-2450

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi